Under the pressure of Chinese medicine collection, what will be the future purchasing trend?

"Pharmaceutical Network Market Analysis" Some time ago, the State Health Insurance Administration held a symposium on the centralized procurement of Chinese medicine, to study and improve the procurement policy, and to promote the reform of procurement methods.
, the industry believes that the pace of Chinese medicine has become more and more close.
this background, the pressure of pharmaceutical companies in the future will increase sharply, especially Chinese medicine enterprises or pharmaceutical enterprises intend to open up Chinese medicine business.
Nate drug collection to promote Chinese medicine enterprises will be more difficult now if the chinese medicine centralized procurement start, will certainly accelerate a wave of Chinese medicine enterprises performance has been affected, or will be in the field of Traditional Chinese medicine to a big shuffle of the concept, is increasingly becoming the industry's Chinese medicine people on the focus of chinese medicine collection concerns.
this is mainly because, for some time now, the local level seems to be more aggressive in the procurement of Chinese medicine and biological products than in the procurement of chemical and biological products.
To Jinhua City, for example, the city's second batch of volume procurement into a total of 180 Chinese medicine, of which 33 are low-cost drugs, including oral, injections, stickers and other dosage forms;
And it is worth noting that Jinhua City on the price reduction range made mandatory provisions, with the generic name of the same product rules containing low-cost chinese medicine set to a high price limit, on the basis of the price limit, the price reduction shall not be less than 10%, of which Chinese medicine is a low-cost medicine, the price reduction shall not be less than 20%.
means that most Chinese medicines, especially single varieties, need to be reduced by at least 20%, except for non-unique low-cost medicines.
addition, Qinghai Province recently released the volume of procurement catalog, in addition to the large varieties of Chinese medicine in the column, participate in the volume of procurement of Chinese medicine quotations have also caused heated discussion.
specifically, its quotation shall not be higher than the current national procurement price, higher than the national procurement price to the low or low provincial current procurement price is considered invalid tender.
from the above-mentioned collection rules, this Qinghai Province with volume procurement, price reduction is the main theme.
to participate in the collection of Chinese medicine, is bound to carry out a large price reduction.
the local price reduction, in fact, caused a lot of enterprises for the price linkage concern: once the selected varieties appear nationwide to low prices, it will lead to a series of price cuts in the market, or will make the development of Chinese medicine enterprises more difficult.
In the future, the national drug centralized procurement target will be aimed at large varieties in fact, with the experience of several batches of chemical drugs, once the collection policy is formally implemented, a substantial reduction in drug prices is inevitable, and for Chinese medicine will be the same.
under the pressure of drug prices will fall greatly, how the future procurement trend will develop has become the focus of the industry.
To this, the industry analysis, from the chemical drug 4 plus 7 sets, collection expansion, the second batch of collection and the upcoming implementation of the third batch of collection, the future trend, will be mainly hospital procurement volume, quality level can be unified varieties, as well as can form a full competition for large varieties, such as 2018 growth momentum of strong Pfizer and Sanofi Bolivi and so on.
According to public data, the cumulative sales of the top 20 varieties of Chinese medicine in the 2019 terminal sales reached 60.1 billion yuan, the top 20 Chinese medicine products, sales are more than 2 billion yuan, most of which are cerebrovascular disease drugs, cardiovascular disease drugs, and include cerebral heart capsules, injection thrombosis (freeze-dry), Danhong injections and more than 10 other unique varieties.
, according to the previous harvest trend, these varieties will have a greater possibility of finalists.
conclusion, Chinese medicine is expected to usher in new development opportunities with the attention and policy support at the national level.
, Chinese medicine will face more new challenges.
Chinese medicine enterprises, we must have the determination of strong men to break their wrists, in the environment to force enterprises to become with research and development innovation ability, we need to accelerate the transformation and upgrading, towards the direction of fine operation.
.